Mineralys Therapeutics (MLYS) issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones. Recent Clinical Highlights and Upcoming Milestones: Explore-OSA Phase 2 Trial; Lorundrostat New Drug Application; Transform-HTN Open-Label Extension Trial; Explore-CKD Phase 2 Trial; Launch-HTN Phase 3 Trial; Advance-HTN Trial
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS: